Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COL-PROBENECID vs PROBENECID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Colchicine binds to tubulin, inhibiting microtubule polymerization and reducing inflammatory cell chemotaxis. Probenecid inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion and lowering serum urate levels.
Inhibits renal tubular reabsorption of uric acid, increasing its excretion and lowering serum urate levels. Also inhibits renal tubular secretion of weak acids (e.g., penicillins, cephalosporins).
Treatment of gout flares,Prophylaxis of gout flares,Hyperuricemia associated with gout (probenecid component)
FDA: Treatment of hyperuricemia associated with gout (prophylaxis and chronic management), adjunct to penicillin or cephalosporin therapy to elevate and prolong antibiotic levels.,Off-label: Prevention of nephropathy in patients with hyperuricemia, adjunct to antiviral agents (e.g., cidofovir) to reduce nephrotoxicity.
Each tablet contains 0.5 mg colchicine and 500 mg probenecid. For gout prophylaxis, 1 tablet orally once daily, increasing to 1 tablet twice daily if needed. For acute gout flares, 2 tablets initially, then 1 tablet every 2 hours until relief or gastrointestinal symptoms occur, with a maximum of 8 tablets per flare.
Oral: 250 mg twice daily for 1 week, then 500 mg twice daily; for gout prophylaxis, initial 250 mg twice daily for 3-4 weeks then increase to 500 mg twice daily; for hyperuricemia secondary to thiazide diuretics, 250 mg twice daily.
Colchicine: terminal half-life 20-30 hours (up to 40-60 hours in renal impairment). Probenecid: 6-12 hours (dose-dependent, prolonged in renal disease).
Terminal elimination half-life is approximately 6-12 hours in adults with normal renal function; may be prolonged in renal impairment or older adults.
Colchicine is metabolized primarily by CYP3A4 and to a lesser extent by CYP2D6. Probenecid is metabolized via glucuronidation and oxidation; it inhibits renal tubular secretion of many drugs and inhibits the metabolism of some drugs.
Primarily hepatic via oxidation and glucuronidation; minor renal metabolism.
Colchicine: ~65% renal excretion as unchanged drug and metabolites; 10-20% biliary excretion. Probenecid: ~77-88% renal excretion (primarily as glucuronide conjugate); <15% biliary/fecal.
Renal excretion of unchanged drug and metabolites; ~77% of dose recovered in urine within 48 hours (50% as glucuronide conjugates, 27% as unchanged probenecid); ~11% excreted in feces via biliary elimination.
Colchicine: 30-50% bound to albumin. Probenecid: 85-95% bound to albumin.
Approximately 75-95% bound to plasma albumin.
Colchicine: Vd 2-4 L/kg (extensive tissue distribution, high affinity for tubulin). Probenecid: Vd 0.2-0.4 L/kg (limited extravascular distribution).
Apparent volume of distribution is about 9 L (approximately 0.13 L/kg in adults); indicates limited extravascular distribution, primarily confined to plasma and extracellular fluid.
Colchicine: Oral bioavailability ~50% (wide interindividual variability). Probenecid: Oral bioavailability ~100%.
Oral bioavailability is nearly complete (>90%) with peak plasma concentrations achieved within 2-4 hours.
Contraindicated in patients with Cr Cl < 50 m L/min. Use not recommended in severe renal impairment.
GFR 10-50 m L/min: 250 mg once daily or 500 mg every 12-24 hours; GFR <10 m L/min: avoid use; anuria: contraindicated.
Avoid use in Child-Pugh class B or C due to risk of colchicine accumulation. Use with caution in mild hepatic impairment, consider reducing dose.
No specific adjustment recommended; use caution in severe hepatic impairment.
Not recommended for use in children (safety and efficacy not established).
For gout or hyperuricemia (children >2 years): 25 mg/kg/day (max 2 g/day) divided every 6-8 hours; as adjunct to penicillin/cephalosporin: 25 mg/kg/day (max 2 g/day) divided every 8 hours for infants >3 months and children; neonates: dose not established.
Use with caution due to increased risk of renal impairment and accumulation. Start at lower doses (e.g., 1 tablet daily). Monitor renal function and for myelosuppression.
Start at lowest dose (250 mg once daily) due to age-related renal impairment; monitor renal function regularly; avoid if GFR <30 m L/min.
None
None.
Fatal overdoses have been reported with colchicine; do not exceed recommended dose.,Severe toxicity can occur with concomitant use of CYP3A4 or P-glycoprotein inhibitors.,Monitor renal function; dose adjustment required in renal impairment.,Hematologic toxicity (bone marrow suppression) with probenecid.,Uric acid stone formation; ensure adequate hydration and alkalinization of urine.,Drug interactions: colchicine with statins, macrolides, antifungals; probenecid with NSAIDs, penicillins, methotrexate.
Use with caution in patients with peptic ulcer disease.,May worsen acute gouty arthritis; prophylactic colchicine or NSAIDs recommended during initiation.,Risk of uric acid stone formation; ensure adequate hydration and alkalinize urine if needed.,Avoid use in patients with blood dyscrasias or bone marrow depression.,May interfere with urine glucose and ketone tests.
Hypersensitivity to colchicine or probenecid,Severe renal impairment (Cr Cl <10 m L/min),Hepatic impairment (colchicine),Blood dyscrasias (probenecid),Concurrent use of P-glycoprotein or CYP3A4 strong inhibitors (e.g., clarithromycin, ketoconazole) with colchicine
Hypersensitivity to probenecid or any component.,Severe renal impairment (Cr Cl <50 m L/min) or anuria.,History of uric acid kidney stones.,Concomitant use with methotrexate (increases methotrexate toxicity).,Use during acute gouty attack (unless already on therapy).
Avoid or limit intake of high-purine foods (organ meats, anchovies, sardines, mussels, yeast extracts) as they may precipitate gout attacks. Alcohol (especially beer and spirits) increases urate production and decreases urate excretion, raising gout risk. Take with food to minimize gastrointestinal irritation.
Avoid high-purine foods (organ meats, sardines, anchovies, shellfish, red meat) as they increase uric acid levels. Limit alcohol, especially beer and spirits, which increase uric acid. Maintain high fluid intake (water, citrus juices) to promote urine flow and prevent stones. Avoid cranberry juice as it may acidify urine.
Pregnancy Category D (probenecid) and C (colchicine). First trimester: Colchicine associated with increased risk of chromosomal abnormalities and neural tube defects. Second and third trimesters: Probenecid may cause fetal harm including nephrotoxicity and growth restriction. Colchicine may cause fetal toxicity at high doses.
Probenecid is FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies exist. Use only if clearly needed. First trimester: No known teratogenic effects. Second and third trimesters: No specific fetal risks documented; avoid near term due to potential for neonatal hyperbilirubinemia (displaces bilirubin from albumin).
Colchicine: M/P ratio 0.93; small amounts excreted, monitor infant for gastrointestinal effects. Probenecid: Not recommended; M/P ratio unknown; avoid due to potential renal effects in infant.
Probenecid is excreted into breast milk in low concentrations; M/P ratio not available. Consider benefits of breastfeeding versus potential risk of adverse effects in infant (e.g., rash, gastrointestinal effects). Use with caution.
Colchicine: Dose may need reduction due to increased volume of distribution and decreased clearance; monitor for toxicity. Probenecid: Dose adjustment may be needed due to increased renal clearance; monitor uric acid levels.
No formal pharmacokinetic studies during pregnancy. Dose adjustment not routinely recommended, but consider decreased efficacy due to increased renal clearance in pregnancy. Monitor clinical response and adjust dose if needed.
Colchicine and probenecid combination is used for gout prophylaxis and treatment. Monitor renal function closely; probenecid is contraindicated in Cr Cl <50 m L/min. Colchicine has a narrow therapeutic index and is contraindicated in patients with hepatic or renal impairment unless dose-adjusted. Avoid concurrent use of strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) which increase colchicine toxicity. Probenecid inhibits tubular secretion of many drugs (e.g., penicillins, methotrexate), increasing their levels.
Probenecid inhibits renal tubular secretion of uric acid, increasing its excretion; used for chronic gout, not acute attacks. It also reduces renal excretion of penicillins and cephalosporins, so it is used to increase serum levels of these antibiotics. Ensure adequate hydration (at least 2-3 L daily) to prevent urate nephropathy. Avoid in patients with creatinine clearance <50 m L/min, history of uric acid stones, or acute gout attack. Alkalinization of urine (urine p H 6.5-7) reduces stone risk. Monitor serum uric acid, renal function, and CBC. Drug interactions: potentiates toxicity of methotrexate, NSAIDs, thiazides, salicylates (salicylates antagonize uricosuric effect).
Take with food to reduce GI upset.,Drink plenty of fluids (at least 2-3 liters daily) to prevent kidney stones.,Report unusual bruising, bleeding, or signs of infection immediately.,Avoid alcohol as it increases serum urate levels and GI irritation.,Do not use this medication during a gout flare; wait until flare resolves.,Colchicine overdose can be fatal; seek emergency care if more than prescribed dose is taken.,Probenecid may cause false-positive urine glucose test with Clinitest.
Take probenecid with food or antacids to reduce GI upset.,Drink at least 8-10 glasses of water daily while on this medication.,Do not take aspirin or other salicylates; they can reduce the effect.,This drug may increase bleeding risk if you take blood thinners like warfarin.,Report any signs of allergic reaction, rash, or fever immediately.,Avoid alcohol as it increases uric acid levels.,Tell your doctor before taking other medications, especially antibiotics.,Do not use during an acute gout attack; wait until attack resolves.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Store at room temperature, away from moisture and heat.
"Edoxaban, a direct factor Xa inhibitor, may inhibit organic anion transporters (OATs) involved in the renal excretion of probenecid, leading to increased probenecid plasma concentrations. Elevated probenecid levels can enhance its uricosuric effect and potentially increase the risk of adverse effects such as gastrointestinal disturbances and hypersensitivity reactions. Clinicians should be aware of this interaction when coadministering these agents, particularly in patients with renal impairment."
"Acemetacin, a nonsteroidal anti-inflammatory drug (NSAID) and prodrug of indomethacin, reduces renal clearance of probenecid by inhibiting tubular secretion and possibly competing for organic anion transporters. This leads to increased plasma concentrations of probenecid, prolonging its half-life and enhancing its uricosuric effect. Clinically, this interaction may result in elevated risk of probenecid toxicity, including gastrointestinal discomfort, rash, or rare blood dyscrasias, while also potentially increasing the anti-inflammatory effects of acemetacin."
"Cilostazol, a phosphodiesterase III inhibitor, can inhibit the renal tubular secretion of probenecid, a uricosuric agent, thereby decreasing its clearance and increasing its serum concentration. This elevation may potentiate the effects and toxicity of probenecid, including an increased risk of uric acid nephropathy and gastrointestinal disturbances. The interaction is of particular concern in patients with renal impairment or those receiving concurrent nephrotoxic drugs."
"Edoxaban, a direct factor Xa inhibitor, may inhibit organic anion transporters (OATs) involved in the renal excretion of probenecid, leading to increased probenecid plasma concentrations. Elevated probenecid levels can enhance its uricosuric effect and potentially increase the risk of adverse effects such as gastrointestinal disturbances and hypersensitivity reactions. Clinicians should be aware of this interaction when coadministering these agents, particularly in patients with renal impairment."
"Acemetacin, a nonsteroidal anti-inflammatory drug (NSAID) and prodrug of indomethacin, reduces renal clearance of probenecid by inhibiting tubular secretion and possibly competing for organic anion transporters. This leads to increased plasma concentrations of probenecid, prolonging its half-life and enhancing its uricosuric effect. Clinically, this interaction may result in elevated risk of probenecid toxicity, including gastrointestinal discomfort, rash, or rare blood dyscrasias, while also potentially increasing the anti-inflammatory effects of acemetacin."
"Cilostazol, a phosphodiesterase III inhibitor, can inhibit the renal tubular secretion of probenecid, a uricosuric agent, thereby decreasing its clearance and increasing its serum concentration. This elevation may potentiate the effects and toxicity of probenecid, including an increased risk of uric acid nephropathy and gastrointestinal disturbances. The interaction is of particular concern in patients with renal impairment or those receiving concurrent nephrotoxic drugs."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COL-PROBENECID vs PROBENECID, answered by our medical review team.
COL-PROBENECID is a Uricosuric that works by Colchicine binds to tubulin, inhibiting microtubule polymerization and reducing inflammatory cell chemotaxis. Probenecid inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion and lowering serum urate levels.. PROBENECID is a Uricosuric that works by Inhibits renal tubular reabsorption of uric acid, increasing its excretion and lowering serum urate levels. Also inhibits renal tubular secretion of weak acids (e.g., penicillins, cephalosporins).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COL-PROBENECID and PROBENECID depend on the specific clinical indication. These are both Uricosuric agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COL-PROBENECID is: Each tablet contains 0.5 mg colchicine and 500 mg probenecid. For gout prophylaxis, 1 tablet orally once daily, increasing to 1 tablet twice daily if needed. For acute gout flares, 2 tablets initially, then 1 tablet every 2 hours until relief or gastrointestinal symptoms occur, with a maximum of 8 tablets per flare.. The standard adult dose of PROBENECID is: Oral: 250 mg twice daily for 1 week, then 500 mg twice daily; for gout prophylaxis, initial 250 mg twice daily for 3-4 weeks then increase to 500 mg twice daily; for hyperuricemia secondary to thiazide diuretics, 250 mg twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining COL-PROBENECID and PROBENECID. Probenecid inhibits OAT3-mediated renal tubular secretion of phenylbutyrate and its active metabolite phenylacetate, leading to a significant increase in systemic exposure of these metabolites. Elevated phenylacetate levels can enhance the risk of hyperammonemia, neurotoxicity, and gastrointestinal adverse effects, particularly in patients with urea cycle disorders. Concurrent use requires close monitoring for signs of toxicity and dose adjustment of phenylbutyric acid. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. COL-PROBENECID is classified as Category A/B. Pregnancy Category D (probenecid) and C (colchicine). First trimester: Colchicine associated with increased risk of chromosomal abnormalities and neural tube defects. Second and th. PROBENECID is classified as Category A/B. Probenecid is FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies exist. Use only if clearly needed. First trimester: No known . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.